Tazemetostat is an investigational drug that kills cancer cells by stopping
a gene called EZH2 from working. EZH2 affects how two other genes, INI1
and SMARCA4 work in cells.
In early clinical development, tazemetostat has demonstrated clinical activity
and a generally well-tolerated safety profile in both patients with hematological
malignancies and genetically defined solid tumors.
Currently, tazemetostat is being used as a single-agent therapy in multiple
clinical trials, including Phase 2 clinical trials in patients with mesothelioma.
Please click on this link to determine your eligibility and latest clinical